732308-80-4

Usage

Uses

Used in Organic Synthesis:
1-(4-BROMOPHENYL)CYCLOHEXANECARBOXYLIC ACID is used as a key intermediate for the synthesis of various organic compounds. Its unique structure allows for the creation of a wide range of derivatives, contributing to the development of novel chemical entities with diverse applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-(4-BROMOPHENYL)CYCLOHEXANECARBOXYLIC ACID is utilized as a building block for the design and synthesis of pharmaceuticals. Its chemical properties make it suitable for the development of compounds with potential therapeutic effects, aiding in the advancement of new treatments for various diseases.
Used in Drug Discovery and Development:
1-(4-BROMOPHENYL)CYCLOHEXANECARBOXYLIC ACID is employed as a valuable component in drug discovery and development processes. Its potential to form new compounds with biological activity makes it an important tool for researchers seeking to identify and optimize novel drug candidates.
Used in Agrochemicals:
In the agrochemical industry, 1-(4-BROMOPHENYL)CYCLOHEXANECARBOXYLIC ACID is used as a precursor in the synthesis of various agrochemicals. Its versatility in chemical reactions enables the production of compounds with applications in crop protection and pest control, contributing to the development of effective and sustainable agricultural solutions.

Upstream product

• 626603-27-8 1-(4-bromophenyl)cyclohexane-1-carbonitrile 
• 16532-79-9 4-Bromophenylacetonitrile 
• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 1236357-63-3 methyl 1-(4-bromophenyl)cyclohexanecarboxylate 
• 111-24-0 1,5-dibromo-pentane 
• 133017-10-4 Butyl 2-(4-bromophenyl)acetate 

Downstream Products

• 732309-05-6 1-(4-bromophenyl)cyclohexanecarbonyl chloride 

Relevant academic research and scientific papers

GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS

The present invention relates to certain gem-disubstituted heterocyclic compounds, which modulate the activity of Isocitrate Dehydrogenase (IDH). The compounds of this invention are therefore useful in treating diseases caused by mutated IDH1 and/or mutat

EP300/CREBBP INHIBITOR

The present invention provides a compound having excellent histone acetyltransferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein ring Q1, ring Q2, R1, R2, R3 and R4 respectively have the same meanings as defined in the specification.

Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class i HDAC Enzymes and Cancer Cell Proliferation

AR-42 is an orally active inhibitor of histone deacetylases (HDACs) in clinical trials for multiple myeloma, leukemia, and lymphoma. It has few hydrogen bond donors and acceptors but is a chiral 2-arylbutyrate and potentially prone to racemization. We report achiral AR-42 analogues incorporating a cycloalkyl group linked via a quaternary carbon atom, with up to 40-fold increased potency against human class I HDACs (e.g., JT86, IC50 0.7 nM, HDAC1), 25-fold increased cytotoxicity against five human cancer cell lines, and up to 70-fold less toxicity in normal human cells. JT86 was ninefold more potent than racAR-42 in promoting accumulation of acetylated histone H4 in MM96L melanoma cells. Molecular modeling and structure-activity relationships support binding to HDAC1 with tetrahydropyran acting as a hydrophobic shield from water at the enzyme surface. Such potent inhibitors of class I HDACs may show benefits in diseases (cancers, parasitic infections, inflammatory conditions) where AR-42 is active.

AMIDE DERIVATIVES COMPRISING HETEROCYCLOALKYL RING

PROBLEM TO BE SOLVED: To provide compounds or pharmacologically acceptable salts thereof that have excellent EP300 and/or CREBBP histone acetyltransferase inhibitory activity. SOLUTION: The invention provides compounds represented by the formula (1) in the figure or pharmacologically acceptable salts thereof. (In the formula (1), ring Q1, ring Q2, ring Q3, X and L are as defined in the specification.) SELECTED DRAWING: None COPYRIGHT: (C)2020,JPO&INPIT

General and cost-effective synthesis of 1-heteroaryl/arylcycloalkylamines and their broad applications

A general and cost-effective route has been developed to synthesize 1-heteroarylsubstituted cycloalkylamines from readily available heteroarylacetate in good yields. This synthesis features a LHMDS promoted cyclization and one-pot hydrolysis/Curtius rearr

CARBAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS

This invention pertains to certain carbamic acid compounds of the formula (I), which inhibit HDAC (histone deacetylase) activity: wherein: J is a linking functional group and is independently: -O-C(=O)- or -C(=O)-O- or - C(=O)-; Cy is a cyclyl group and is independently: C3-20carbocyclyl, C3-20heterocyclyl, or C5-20aryl; and is optionally substituted; Q1 is a cyclyl leader group, and is independently a divalent bidentate group obtained by removing two hydrogen atoms from a ring carbon atom of a saturated monocyclic hydrocarbon having from 4 to 7 ring atoms, or by removing two hydrogen atoms from a ring carbon atom of saturated monocyclic heterocyclic compound having from 4 to 7 ring atoms including 1 nitrogen ring atom or 1 oxygen ring atom; and is optionally substituted; Q2 is an acid leader group, and is independently: C1-8alkylene; and is optionally substituted; or: Q2 is an acid leader group, and is independently: C5-20arylene; C5-20arylene-C1-7alkylene; C1-7alkylene-C5-20arylene; or C1-7alkylene-C5-20arylene-C1-7alkylene; and is optionally substituted; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC,and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.